Rhumbline Advisers Jounce Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.9 - $1.85 $261 - $536	290 Added 0.46%	63,356 $117,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.99 $40 - $125	-63 Reduced 0.1%	63,066 $70,000
Q3 2022 Nov 10, 2022	BUY	$2.73 - $4.92 $15,528 - $27,984	5,688 Added 9.9%	63,129 $148,000
Q2 2022 Aug 11, 2022	BUY	$2.8 - $7.67 $40,336 - $110,494	14,406 Added 33.48%	57,441 $174,000
Q1 2022 May 12, 2022	SELL	$6.01 - $8.54 $10,114 - $14,372	-1,683 Reduced 3.76%	43,035 $292,000
Q4 2021 Feb 10, 2022	BUY	$7.11 - $9.64 $15,250 - $20,677	2,145 Added 5.04%	44,718 $373,000
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $5,881 - $10,187	1,167 Added 2.82%	42,573 $316,000
Q2 2021 Aug 05, 2021	BUY	$6.58 - $10.66 $89,218 - $144,538	13,559 Added 48.69%	41,406 $282,000
Q1 2021 May 06, 2021	SELL	$6.73 - $13.87 $7,066 - $14,563	-1,050 Reduced 3.63%	27,847 $286,000
Q4 2020 Feb 10, 2021	BUY	$6.37 - $10.33 $23,154 - $37,549	3,635 Added 14.39%	28,897 $202,000
Q3 2020 Nov 12, 2020	SELL	$4.58 - $10.95 $17,436 - $41,686	-3,807 Reduced 13.1%	25,262 $206,000
Q2 2020 Aug 13, 2020	BUY	$4.17 - $7.58 $5,562 - $10,111	1,334 Added 4.81%	29,069 $201,000
Q1 2020 May 06, 2020	BUY	$2.91 - $8.7 $7,071 - $21,141	2,430 Added 9.6%	27,735 $132,000
Q4 2019 Feb 05, 2020	BUY	$2.81 - $9.21 $775 - $2,541	276 Added 1.1%	25,305 $221,000
Q3 2019 Oct 23, 2019	BUY	$3.33 - $4.93 $6,973 - $10,323	2,094 Added 9.13%	25,029 $83,000
Q2 2019 Aug 14, 2019	BUY	$4.3 - $6.73 $14,383 - $22,511	3,345 Added 17.08%	22,935 $114,000
Q1 2019 May 01, 2019	BUY	$3.43 - $6.87 $1,505 - $3,015	439 Added 2.29%	19,590 $121,000
Q4 2018 Jan 31, 2019	BUY	$2.69 - $6.71 $14,552 - $36,301	5,410 Added 39.37%	19,151 $65,000
Q3 2018 Nov 07, 2018	SELL	$6.5 - $8.37 $6,500 - $8,370	-1,000 Reduced 6.78%	13,741 $89,000
Q2 2018 Aug 06, 2018	BUY	$7.27 - $21.88 $13,987 - $42,097	1,924 Added 15.01%	14,741 $113,000
Q1 2018 May 02, 2018	BUY	$13.4 - $28.4 $31,155 - $66,030	2,325 Added 22.16%	12,817 $286,000
Q4 2017 Feb 09, 2018	BUY	$12.52 - $17.82 $131,359 - $186,967	10,492	10,492 $134,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account